Production of the Sputnik V vaccine against coronavirus will begin in India this summer, the Russian Direct Investment Fund (RDIF) and pharmaceutical company Panacea Biotec announced on Monday.Sputnik V was registered in India under the .
COVID-19: Panacea Biotec, RDIF to start Sputnik V production in India
RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V. File photo
Updated: May 24, 2021, 05:46 PM IST
Panacea Biotec, one of India s largest pharmaceutical companies and the Russian Direct Investment Fund (RDIF) of Russia have taken a major decision to increase the production of coronavirus vaccine in the country. The two companies have announced that they will produce 100 million doses of 100 million Russian Sputnik V every year.
In a statement, Panacea Biotec Ltd (PBL) said that it will produce the Sputnik V in India in association with RDIF. The fund will be arranged by RDIF under the agreement, while the vaccines will be produced in Panacea units. The production of the Sputnik V vaccine will begin in India this summer.
Russia s Sputnik V Covid vax to be available in market from next week: Govt
By IANS |
4 Views
New Delhi, May 13 : The Union Health Ministry on Thursday announced that Russia s Sputnik V, the vaccine against the Covid-19 pandemic, will be available in markets across the country early next week.
The announcement comes 12 days after the first consignment of 150,000 doses of the Sputnik V vaccine landed in Hyderabad from Russia. Sputnik V is developed by Russia s Gamaleya National Center. It will be the third vaccine to be cleared for use in India at a time when the country is in the grip of an intense second wave and demand for vaccines has shot up.
Coronavirus-Liveticker: +++ 01:35 Handwerkspräsident fordert zusätzliche Wirtschaftshilfen +++ n-tv.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from n-tv.de Daily Mail and Mail on Sunday newspapers.